Is the weight-loss industry becoming a race to the bottom? Novo Nordisk recently criticized its competitor, Hims & Hers, for offering a cheaper weight-loss pill at just $49 a month. While affordability is essential, can we trust that a lower price doesn’t compromise the quality or efficacy of the treatment? With such drastic price differences, it raises questions about the motivation behind these pricing strategies and what they mean for consumers in the long run. If you're looking for budget-friendly options, how do you navigate potential risks with cheaper alternatives? What do you think – is saving money worth the potential trade-offs in your health? https://www.ft.com/content/3a1deeee-f097-4841-9b93-a4293ddba7c6 #WeightLoss #Healthcare #NovoNordisk #HimsAndHers